IDX316

IDX316 is a macrocyclic small molecule inhibitor of the Hepatitis C virus (HCV) NS3/4A protease. Developed by Idenix Pharmaceuticals, it was designed to block the viral replication cycle by preventing the cleavage of the HCV polyprotein into functional proteins. In clinical development, it was evaluated both as a monotherapy and in combination with other direct-acting antivirals (DAAs) such as the nucleotide polymerase inhibitor IDX184, as well as with pegylated interferon and ribavirin. Although it demonstrated potent antiviral activity in early-phase studies, its development was ultimately discontinued as the HCV treatment landscape shifted toward more competitive regimens and the company prioritized other candidates.